MAP2K7 and non-small cell lung carcinoma: Therefore, we postulate that combining EGFR, calcineurin, and MEK inhibitors is a promising therapeutic strategy for treatment of EGFR-mutant NSCLC patients that accumulate PPP3CB after progression on initial EGFR TKI.